Intravitreal Aflibercept for Macular Edema Due to Central Retinal Vein Occlusion
Launched by UNIVERSITY OF ATHENS · May 10, 2024
Trial Information
Current as of April 26, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Treatment naive center-involved macular edema secondary to CRVO for no longer than 3 months.
- • Patients \>18 years of age, who are diagnosed with macular edema secondary to CRVO who are scheduled to be treated with intravitreal aflibercept in real-life conditions
- • BCVA of Snellen of 20/40 to 20/200 in the study eye
- Exclusion Criteria:
- • Previous PRP or macular laser photocoagulation in the study eye.
- • Any prior ocular treatment in the study eye for macular edema secondary to CRVO.
- • Prior systemic anti-VEGF or corticosteroid therapy, within the last 3 months before enrollment to the study.
- • Any active or previous inflammation, ocular trauma
- • Uncontrolled glaucoma (IOP\>30 mmHg)
About University Of Athens
The University of Athens, a leading institution in medical research and education, is dedicated to advancing healthcare through innovative clinical trials. With a robust infrastructure and a multidisciplinary team of experts, the university focuses on translating scientific discoveries into practical applications that benefit patient care. Its commitment to ethical standards and rigorous methodologies ensures that all trials conducted under its auspices adhere to the highest principles of research integrity. By fostering collaboration with national and international partners, the University of Athens aims to contribute significantly to the global medical community and improve health outcomes through evidence-based practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported